BPC
RPRX icon

Banque Pictet & Cie’s Royalty Pharma RPRX Stock Holding History

Banque Pictet & Cie’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,001
Closed -$369K – 504
2023
Q2 		$369K Buy
12,001
+1,167
+11% +$39.5K ﹤0.01% 432
2023
Q1 		$390K Sell
10,834
-4,894
-31% -$181K ﹤0.01% 501
2022
Q4 		$622K Sell
15,728
-754
-5% -$31.5K 0.01% 475
2022
Q3 		$662K Buy
+16,482
New +$704K 0.01% 454

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Banque Pictet & Cie's RPRX Position: Q3 2023 in Review

Banque Pictet & Cie sold out of Royalty Pharma (RPRX) in Q3 2023, closing a stake of 12,001 shares — an estimated $369K sold.

Banque Pictet & Cie first reported a position in RPRX in Q3 2022 and held it in 4 quarters. The position peaked at $662K in Q3 2022. 313 funds tracked by Wall St. Rank hold RPRX as of Q3 2023.

  • Banque Pictet & Cie reported no remaining Royalty Pharma position as of Q3 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 12,001 Royalty Pharma shares in Q3 2023, an estimated $369K.
  • Banque Pictet & Cie first reported a position in Royalty Pharma in Q3 2022 and held it in 4 quarters.
  • Banque Pictet & Cie's Royalty Pharma position peaked at $662K in Q3 2022.
  • 313 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2023.

Based on Banque Pictet & Cie's 13F filing for Q3 2023, filed 2 Nov 2023.